Drugs / PF-08046045
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06120504 | Feb 2024 → Dec 2025 | Hodgkins lymphoma, anaplastic large cell lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified +1 | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06120504 ↗ |
| Route | Intravenous | “The study drug will be given as an infusion through a vein.” NCT06120504 ↗ |